REGULATORY APPROVALS
Deepinder Goyal's $900 Temple wearable faces scrutiny over brain blood-flow claims
Temple, a new wearable device, claims to track blood flow to the brain and other health metrics. Indian doctors express concerns over the validity of these claims, asking for regulatory scrutiny. Some sportspersons promote the device, while critics label it a gimmick without formal medical approvals. Developer Deepinder Goyal states the device is a wellness tracker, not a medical one.
Deutsche Bank launches digital asset custody service for paying clients
Deutsche Bank launches its digital asset custody service for institutional and corporate clients, offering secure storage for cryptocurrencies including Bitcoin and Ether. The move strengthens its digital asset strategy, with plans for potential Asian expansion and collaboration with DWS to develop regulated digital asset infrastructure.
IIFL Finance shares rally 5% as Blackstone leads Rs 6,414 crore capital infusion
IIFL Finance shares surged on Wednesday after the company announced a Rs 6,414 crore capital infusion led by Blackstone, which will invest Rs 5,000 crore. The fundraise, also involving promoter investments and Anchorage Capital, aims to strengthen capital adequacy, lower funding costs and accelerate growth in secured lending.
Cochin Shipyard net profit falls 50% to Rs 54 crore in Q2
Cochin Shipyard Ltd reported a 50% decline in consolidated net profit for the September quarter of FY27. The company's net profit fell to Rs 53.77 crore compared to Rs 107.52 crore a year earlier. However, total income increased to Rs 1,331.81 crore from Rs 1,245.88 crore during the same period. Total expenses also rose to Rs 1,256.71 crore compared to Rs 1,095.97 crore previously.
India drawing up list of export snags in South Asia
India is identifying regulatory and market-access barriers in seven South Asian countries to expand exports and reach its $1-trillion target. Merchandise exports to these markets fell 1.3% to $25.7 billion in FY26. The government is examining certification delays, tariffs and product standards while exploring opportunities in chemicals, pharmaceuticals and textiles.
Amazon's Ring Drone Cam took six years to arrive but you can't buy the $249 security drone yet-here's why
Amazon's Ring has launched its new Ring Drone Cam, a flying indoor security camera first announced six years ago. Priced at $249.99, it is expected to ship in the US on January 27, 2027. However, the device still needs FCC approval before customers can purchase or lease it.
IIFL Finance to raise Rs 6,414 crore through preferential issue; Blackstone to invest Rs 5,000 crore
IIFL Finance approved a Rs 6,414 crore capital raise led by Blackstone, which will invest Rs 5,000 crore for an approximately 16% stake. Promoters Nirmal Jain and R Venkataraman will collectively invest Rs 1,264 crore through warrants.
Bajaj Finance issues 5.74 crore warrants to promoter for Rs 5,799 crore
Bajaj Finance has allotted 5.74 crore warrants to its promoter, Bajaj Finserv, for Rs 5,799 crore. The special committee of the board approved the issue at an issue price of Rs 1,010 per warrant. Each warrant is convertible into an equivalent number of equity shares of the company. A minimum of 25 percent of the consideration is payable at allotment, while the remaining 75 percent will be payable later.
Ozempic Zepbound eye risk warnings: Diabetes, weight-loss drugs Novo Nordisk's Ozempic, Wegovy, Eli Lilly's Mounjaro, Zepbound pose potential threat to eye, sudden vision loss, warns US FDA
Eli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy were under scanner of United States Food and Drug Administration (US FDA).
MakeMyTrip's India arm gets Sebi nod to float IPO
MakeMyTrip's India subsidiary, MMT India, has received approval from Sebi for an initial public offering. This approval follows a confidential filing of draft papers made in July. The IPO will involve the sale of equity shares by MakeMyTrip and its subsidiary, ibibo Group Holdings. Proceeds from the sale are expected to enhance the cash position of the parent company.
Gland Pharma shares jump 4% after Q2 profit jumps 58%, revenue rises 23% YoY
Gland Pharma shares rose 3.89% after reporting strong Q2 FY27 results, with revenue growing 23% and net profit jumping 58% year-on-year. The stock touched a 52-week high of Rs 3,345, supported by robust CDMO growth, improved margins, new product launches and increased US regulatory approvals.
Scripbox shareholders approve conversion into public company ahead of IPO
At an extraordinary general meeting on October 19, shareholders approved the change of the Accel-backed startup's name from Scripbox Wealth Managers Private Limited to Scripbox Wealth Managers Limited, along with amendments to its constitutional documents, according to regulatory filings reviewed by ET.
Herjit Bhalla joins Dabur board as CEO Mohit Malhotra steps down
Dabur India has announced a leadership transition, with Global CEO and Whole-time Director Mohit Malhotra resigning from his positions effective November 13, 2026, after more than three decades with the company. Malhotra is set to take up a leadership role overseas. Dabur has appointed India business CEO Herjit Singh Bhalla as Additional Director and Whole-time Director for five years, effective November 14, subject to regulatory approvals.
Big Tech barely moved after the midterms, but Tesla and SpaceX fell up to 5%, and even Tesla missed the solar rally: Did Elon Musk’s big bet on Republicans just backfire?
Tesla and SpaceX shares fell in premarket trading on Wednesday, Nov. 4: Today’s US stock futures pointed to a strong Wall Street opening, with Dow futures up nearly 800 points and S&P 500 and Nasdaq futures also in the green. However, Tesla and SpaceX moved in the opposite direction, falling more than 5% and nearly 8%, respectively, in premarket trading after the Democratic midterm victory. Alphabet, Meta and Microsoft gained, while Nvidia slipped slightly.
Wockhardt seeks 14-year data shield for India-made drugs
Mumbai-based Wockhardt has struck success in its innovative research on a range of antibiotic drugs, bridging a global pipeline gap for difficult-to-treat infections. In May this year, the company secured approvals from Indian and US drug regulators for a breakthrough drug, Zaynich (cefepime + zidebactam), to treat complicated urinary tract infection, including acute pyelonephritis or severe kidney infections. Wockhardt has showcased six drugs to treat antimicrobial resistance (AMR).
Polymarket unit gets US industry organization's approval to be futures broker
Polymarket has received approval from the National Futures Association for PM Derivatives LLC to act as a broker. This approval allows the company to expand its operations if it obtains further approval from the Commodity Futures Trading Commission. The firm is actively under investigation by the CFTC regarding its marketing practices. Currently, Polymarket serves as a popular platform for betting on various events and elections.
Irdai tightens ESOP norms, share transfer rules for insurers
Irdai has implemented stricter rules regarding employee stock option plans for insurance companies to regulate ownership stakes. Senior executives and directors must seek approval to exceed prescribed shareholding limits under these plans. Insurers are required to monitor direct and indirect share allotments to prevent regulatory breaches.
Govt consults seed, fertiliser firms on easing regulatory hurdles
The Indian government is engaging with agricultural companies to address regulatory challenges that affect the sector. Consultations focus on updating the Seeds Act, 1966, to align with modern agricultural technology. Industry representatives have pointed out delays in approvals and licensing processes that hinder market access.
Yoga Bar maker Sproutlife Foods to merge with ITC; board approves scheme
ITC Ltd has received board approval for a scheme to merge Sproutlife Foods into its operations. This move is designed to streamline business processes and enhance value creation for ITC. Sproutlife, focusing on health-centric food products, achieved a turnover of Rs 451.71 crore in FY26. ITC clarified that no new shares will be issued in this merger, set to be effective from April 1, 2026.
Load More
